Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Jacobson

Showing results (141-150 of 144) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 144 results.
HIV Clinical Trials|September 30, 2005
The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapyD A Wohl, M A Kendall, S Owens, et al.
The Journal of Infectious Diseases|January 7, 1998
A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study GroupJ E Feinberg, S Hurwitz, D Cooper, et al.
Archives of Internal Medicine|May 20, 1998
Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USAR J Whitley, M A Jacobson, D N Friedberg, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 1999
Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potencyP D Williams, M G Bock, B E Evans, et al.
Pageof 15

Showing results (141-150 of 144) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 144 results.
HIV Clinical Trials|September 30, 2005
The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapyD A Wohl, M A Kendall, S Owens, et al.
The Journal of Infectious Diseases|January 7, 1998
A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study GroupJ E Feinberg, S Hurwitz, D Cooper, et al.
Archives of Internal Medicine|May 20, 1998
Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USAR J Whitley, M A Jacobson, D N Friedberg, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 1999
Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potencyP D Williams, M G Bock, B E Evans, et al.
Pageof 15